Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 7/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9106400 | 0.86 | PDE5A (0.38) | GCKNAMPTCHRM2CHRM3NPC1 | |
| SCHEMBL9108554 | 0.86 | NAMPT (0.37) | NAMPTNPC1RAB9A | |
| SCHEMBL9104376 | 0.86 | GRN (0.39) | CRHR1GCKNAMPT | |
| SCHEMBL9106741 | 0.84 | OPRM1 (0.44) | — | |
| SCHEMBL9105977 | 0.83 | HTR2A (0.36) | RAB9A | |
| SCHEMBL9105910 | 0.80 | GCK (0.51) | GCKNPC1 | |
| SCHEMBL9106742 | 0.80 | GCK (0.53) | GCKCHRM2CHRM3 | |
| SCHEMBL9108699 | 0.80 | GCK (0.52) | GCK | |
| SCHEMBL9908121 | 0.80 | GCK (0.52) | GCK | |
| SCHEMBL9105332 | 0.80 | GCK (0.61) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | GPR119, INSR, OAT | CCR5 3395/4885CRHR1 2258/4885CRHR2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.